These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22924678)

  • 41. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial.
    Schwid SR; Goodman AD; Weinstein A; McDermott MP; Johnson KP;
    J Neurol Sci; 2007 Apr; 255(1-2):57-63. PubMed ID: 17331542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006.
    Byrne S; Mason D
    N Z Med J; 2012 Feb; 125(1350):37-44. PubMed ID: 22382255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glatiramer acetate and interferon beta-1b: a study of outcomes among patients with multiple sclerosis.
    Castelli-Haley J; Oleen-Burkey MA; Lage MJ; Johnson KP
    Adv Ther; 2009 May; 26(5):552-62. PubMed ID: 19444392
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis.
    Prosperini L; Giannì C; Leonardi L; De Giglio L; Borriello G; Galgani S; Pozzilli C; Gasperini C
    Mult Scler; 2012 Jan; 18(1):64-71. PubMed ID: 21828195
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study.
    Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E;
    Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
    Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG
    Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis.
    Jones JL; Scheidt DJ; Kaushal RS; Carroll CA
    J Med Econ; 2013; 16(2):213-20. PubMed ID: 23098539
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Impact of Disease-Modifying Therapy Access Barriers on People With Multiple Sclerosis: Mixed-Methods Study.
    Simacek KF; Ko JJ; Moreton D; Varga S; Johnson K; Katic BJ
    J Med Internet Res; 2018 Oct; 20(10):e11168. PubMed ID: 30377144
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Zipoli V; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Lepore V; Livrea P; Comi G; Amato MP;
    Ann Neurol; 2009 Oct; 66(4):513-20. PubMed ID: 19847899
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of fingolimod versus interferon beta-1a for relapsing remitting multiple sclerosis in the United States.
    Lee S; Baxter DC; Limone B; Roberts MS; Coleman CI
    J Med Econ; 2012; 15(6):1088-96. PubMed ID: 22583065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience.
    Pozzilli C; Prosperini L; Sbardella E; De Giglio L; Onesti E; Tomassini V
    Neurol Sci; 2005 Dec; 26 Suppl 4():S174-8. PubMed ID: 16388353
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Coping strategy and anxiety evolution in multiple sclerosis patients initiating interferon-beta treatment.
    Moreau T; Schmidt N; Joyeux O; Bungener C; Souvignet V
    Eur Neurol; 2009; 62(2):79-85. PubMed ID: 19521082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.
    Comabella M; Craig DW; Morcillo-Suárez C; Río J; Navarro A; Fernández M; Martin R; Montalban X
    Arch Neurol; 2009 Aug; 66(8):972-8. PubMed ID: 19667218
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment satisfaction with disease-modifying therapy is the only predictor of Adherence among multiple sclerosis patients from Upper Egypt.
    Khedr EM; Mahmoud DM; Hussein HB; Malky IEL; Mostafa SS; Gamea A
    Sci Rep; 2024 Mar; 14(1):7027. PubMed ID: 38528018
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Update on current care guidelines: multiple sclerosis].
    Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of socioeconomic factors on access to disease modifying treatment in a Norwegian multiple sclerosis cohort.
    Flemmen HØ; Simonsen CS; Broch L; Brunborg C; Berg-Hansen P; Moen SM; Kersten H; Celius EG
    Mult Scler Relat Disord; 2022 May; 61():103759. PubMed ID: 35358792
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Medication adherence/persistence among patients with active multiple sclerosis in Finland.
    Lahdenperä S; Soilu-Hänninen M; Kuusisto HM; Atula S; Junnila J; Berglund A
    Acta Neurol Scand; 2020 Dec; 142(6):605-612. PubMed ID: 32559310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis.
    Tan H; Cai Q; Agarwal S; Stephenson JJ; Kamat S
    Adv Ther; 2011 Jan; 28(1):51-61. PubMed ID: 21153000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.